Catalent wants to build on its European expansions by replicating the end-to-end drug development services model in emerging markets.
Speaking to Outsourcing-Pharma at DIA Euromeeting in Denmark, VP of global regulatory consulting Carolyn Finkle said recent expansions in the UK and Germany are intended to copy its “one-stop-shop” services in the US for European customers.
But Europe is not the only target for Catalent – the firm has set its sights on providing an end-to-end drug development service globally, with future focus on emerging markets, said Finkle. Catalent spoke last year of its interest in expanding in China and India through acquisitions.
“We are also looking to establish bases in emerging countries where clients are looking at bringing their products,” Finkle said. New services will accompany the geographic expansion to make Catalent "a solutions provider rather than a transactional vendor,” she said.
Of the latest expansion in Swindon she said: “This will provide a host of analytical services for companies developing products in Europe, who want to do method development analytical testing, and stability testing.”
The new capabilities coincide with the growth of the company’s regulatory services, including a recent expansion of provisions in the US.
“We basically can help from very early stage development, to later down facilitating some of the full applications, like interacting with the marketing authorisation authority in Europe or the NDA (new drug application) in the US”.